Related Experiment Videos
B19 parvovirus
1Hematology Branch, National Heart, Lung & Blood Institute, Bethesda, MD 20892, USA.
Bailliere'S Clinical Haematology
|March 1, 1995
Summary
Human parvovirus B19 causes various blood disorders by infecting erythroid progenitor cells. Treatments include immunoglobulin for persistent infections, and recombinant capsids show vaccine potential.
Area of Science:
- Virology
- Hematology
- Immunology
Background:
- Human parvovirus B19 (B19) is a significant human pathogen.
- It is associated with diverse clinical manifestations, particularly hematological diseases.
Purpose of the Study:
- To elucidate the pathogenic mechanisms of B19 parvovirus.
- To identify the target cells and immune responses involved in B19 infection.
- To explore potential therapeutic and prophylactic strategies.
Main Methods:
- Propagation of B19 parvovirus in human bone marrow, blood, and fetal liver cell cultures.
- Analysis of viral cytotoxicity through nonstructural protein expression.
- Evaluation of humoral immunity in infection termination.
- Production of recombinant capsids using a baculovirus system.
Main Results:
- B19 parvovirus specifically targets human erythroid progenitor cells.
- Viral nonstructural protein expression leads to cytotoxic effects.
- Humoral immunity is crucial for clearing the infection.
- Commercially available immunoglobulin can treat persistent B19 infections.
- Recombinant B19 capsids are viable vaccine candidates.
Conclusions:
- B19 parvovirus infection poses a significant threat, causing aplastic crisis, hydrops fetalis, and pure red cell aplasia.
- Understanding viral-host interactions and immune responses is key to managing B19 infections.
- Immunoglobulin therapy and potential B19 vaccines offer promising avenues for treatment and prevention.